Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System
Bioconjugate Chemistry · 2024
DOI: 10.1021/acs.bioconjchem.4c00050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Tuersunayi Abudureheman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, Ch…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, B-Cell, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Innovative Research Team of High-level Local University in Shanghai, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Chimeric antigen receptor T-cell (CAR-T cell) therapy has become a promising treatment option for B-cell hematological tumors. However, few optional target antigens and disease relapse due to loss of target antigens limit the broad clinical applicability of CAR-T cells. Here, we conjugated an antibody (Ab) fusion protein, consisting of an Ab domain and a SpyCatcher domain, with the FITC-SpyTag (FITC-ST) peptide to form a bispecific safety switch module using a site-specific conjugation system. We applied the safety switch module to target CD19, PDL1, or Her2-expressing tumor cells by constructing FMC63 (anti-CD19), antiPDL1, or ZHER (anti-Her2)-FITC-ST, respectively. Those switch modules significantly improved the cytotoxic effects of anti-FITC CAR-T cells on tumor cells. Additionally, we obtained the purified CD8+ T cells by optimizing a shorter version of the CD8-binding aptamer to generate anti-FITC CD8-CAR-T cells, which combined with the CD4-FITC-ST switch module (anti-CD4) to eliminate the CD4-positive tumor cells in vitro and in vivo. Overall, we established a novel safety switch module by site-specific conjugation to enhance the antitumor function of universal CAR-T cells, thereby expanding the application scope of CAR-T therapy and improving its safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, China.
- Fujian Branch of Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, and Fujian Children's Hospital, Fuzhou 350001, China.
ORCID-Profile: Kai-Ming Chen
Förderung
- National Key Research and Development Program of China
- Innovative Research Team of High-level Local University in Shanghai
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Program of Shanghai Academic Research Leader
- Science and Technology Commission of Pudong New Area Foundation
- Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province
Zitieren
APA
Abudureheman, T., Zhou, H., Yang, L. T., Huang, X. S., Jing, J. J., Duan, C. W., & Chen, K. M. (2024). Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00050
Vancouver
Abudureheman T, Zhou H, Yang LT, Huang XS, Jing JJ, Duan CW, et al. Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00050
BibTeX
@article{Abudureheman2024,
author = {Abudureheman, Tuersunayi and Zhou, Hang and Yang, Li-Ting and Huang, Xiu-Song and Jing, Jun-Jie and Duan, Cai-Wen and Chen, Kai-Ming},
title = {Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System},
journal = {Bioconjugate Chemistry},
year = {2024},
doi = {10.1021/acs.bioconjchem.4c00050}
}
EUVIMED